查看“FOLFIRINOX”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>FOLFIRINOX</strong> 是一种强效的四药联合<strong>化疗方案</strong>，被誉为胰腺癌治疗的“重型武器”。其名称源自四种组成药物：<strong>Fol</strong>inic acid（亚叶酸钙）、<strong>F</strong>luorouracil（氟尿嘧啶）、<strong>Ir</strong>inotecan（伊立替康）和 <strong>Ox</strong>aliplatin（奥沙利铂）。
            <br>该方案实际上是 <strong>[[FOLFIRI]]</strong> 和 <strong>[[FOLFOX]]</strong> 的叠加。2011 年发表的 <strong>PRODIGE 4/ACCORD 11</strong> 研究证实，FOLFIRINOX 是首个在转移性胰腺导管腺癌（PDAC）中显著优于<strong>[[吉西他滨]]</strong>单药的方案，将患者的中位总生存期（OS）从 6.8 个月延长至 11.1 个月。然而，由于其显著的血液学毒性和胃肠道反应，临床上通常仅适用于体能状态良好（ECOG 0-1）的患者，且目前多采用改良版 <strong>mFOLFIRINOX</strong> 以降低毒性。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">FOLFIRINOX</div>
            <div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">5-FU + LV + Irinotecan + Oxaliplatin (点击展开)</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 25px; text-align: center; background-color: #f8fafc;">
                <div style="width: 100px; height: 100px; background-color: #e2e8f0; border-radius: 50%; margin: 0 auto; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em;">
                     
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">胰腺癌化疗的“三驾马车”</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th colspan="2" style="padding: 8px 12px; background-color: #e0f2fe; color: #1e40af; text-align: left; font-size: 0.9em; border-top: 1px solid #bae6fd;">方案概况</th>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">适应症</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">胰腺癌 (PDAC) • 结直肠癌</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">核心成分</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">奥沙利铂 + 伊立替康 + 5-FU</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">给药周期</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">每 2 周 (q2w)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">改良版</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #16a34a;">mFOLFIRINOX (去推注)</td>
                </tr>
                
                <tr>
                    <th colspan="2" style="padding: 8px 12px; background-color: #e0f2fe; color: #1e40af; text-align: left; font-size: 0.9em; border-top: 1px solid #bae6fd;">风险评估</th>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">毒性等级</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #e11d48;"><strong>极高</strong> (需升白针支持)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">患者要求</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">ECOG 0-1, 肝功正常</td>
                </tr>
                 <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569;">主要竞品</th>
                    <td style="padding: 6px 12px; color: #0f172a;">[[AG方案]] (吉西+白紫)</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">方案组成：三药合一的逻辑</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        FOLFIRINOX 并非简单的药物堆砌，而是基于三种药物不同的抗癌机制，产生协同效应，但也带来了毒性的叠加。
    </p>

    <div style="background-color: #f0f9ff; border-left: 5px solid #1e40af; padding: 15px 20px; margin: 20px 0; border-radius: 4px;">
        <ul style="margin: 0; padding-left: 20px; color: #334155;">
            <li style="margin-bottom: 12px;"><strong>奥沙利铂 (Oxaliplatin)：</strong> 破坏 DNA 结构，形成铂-DNA 加合物。副作用主要是<strong>神经毒性</strong>。</li>
            <li style="margin-bottom: 12px;"><strong>伊立替康 (Irinotecan)：</strong> 抑制拓扑异构酶 I，导致 DNA 断裂。副作用主要是<strong>迟发性腹泻</strong>和中性粒细胞减少。</li>
            <li style="margin-bottom: 0;"><strong>5-FU/亚叶酸钙 (LV)：</strong> 持续输注抑制 DNA 合成。副作用主要是粘膜炎和手足综合征。将这三种药放在一起，意在对顽固的胰腺癌细胞进行“地毯式轰炸”。</li>
        </ul>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">mFOLFIRINOX：为了安全而改良</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        原始的 FOLFIRINOX 方案毒性太强，许多患者无法耐受。因此，临床上现在普遍使用<strong>改良版 (modified FOLFIRINOX)</strong>。
    </p>

    <div style="overflow-x: auto; margin: 20px auto;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;">
            <tr style="background-color: #f1f5f9; border-bottom: 2px solid #0f172a;">
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">版本</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af; width: 35%;">给药细节变化</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569; width: 40%;">临床获益</th>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">原始 FOLFIRINOX</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">含 5-FU 推注 (Bolus)</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">中性粒细胞减少症发生率极高 (45.7%)。</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600; color: #16a34a;">mFOLFIRINOX</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;"><strong>取消 5-FU 推注</strong>；<br>有时下调伊立替康剂量 (150 mg/m²)</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">疗效与原版相当，但显著降低了骨髓抑制和胃肠道反应，提高了耐受性。</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">王座之争：FOLFIRINOX vs. AG方案</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        目前胰腺癌一线治疗有两大标准方案：FOLFIRINOX 和 <strong>AG方案</strong>（吉西他滨 + 白蛋白结合型紫杉醇）。如何选择？
    </p>
    <ul style="padding-left: 25px; color: #334155; margin-top: 15px;">
        <li style="margin-bottom: 12px;"><strong>FOLFIRINOX：</strong> 适合<strong>年轻、体能好 (ECOG 0-1)</strong>、无基础疾病的患者。若带有 <strong>BRCA 突变</strong>，含铂的 FOLFIRINOX 更是首选。术后辅助治疗证据更强（PRODIGE 24）。</li>
        <li style="margin-bottom: 12px;"><strong>AG方案：</strong> 适合<strong>体能稍差 (ECOG 2)</strong> 或无法耐受三药联合的老年患者。如果患者对铂类不敏感或有严重神经病变，也倾向于选 AG。</li>
    </ul>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献 [Academic Review]</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Conroy T, et al. (2011).</strong> <em>FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.</em> <strong>[[New England Journal of Medicine]]</strong>. <br>
            <span style="color: #475569;">[点评]：里程碑研究 (PRODIGE 4/ACCORD 11)。首次证明三药联合方案在胰腺癌中优于吉西他滨，尽管毒性增加，但生存获益巨大。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>Conroy T, et al. (2018).</strong> <em>FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.</em> <strong>[[New England Journal of Medicine]]</strong>. <br>
            <span style="color: #475569;">[点评]：PRODIGE 24 研究。将 mFOLFIRINOX 确立为胰腺癌切除术后辅助化疗的新标准，中位 OS 达到惊人的 54.4 个月（vs 吉西他滨 35.0 个月）。</span>
        </p>

        <p style="margin: 12px 0;">
            [3] <strong>Thibault C, et al. (2018).</strong> <em>First-line chemotherapy in advanced pancreatic adenocarcinoma: 5-FU-based triplets.</em> <strong>[[Expert Review of Anticancer Therapy]]</strong>. <br>
            <span style="color: #475569;">[点评]：综述了三药联合方案的演变，重点讨论了 mFOLFIRINOX 在安全性优化方面的优势。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            肿瘤化疗方案 · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">上级分类</td>
                <td style="padding: 10px 15px; color: #334155;">[[化疗]] • 胰腺癌标准治疗</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">核心组分</td>
                <td style="padding: 10px 15px; color: #334155;">[[奥沙利铂]] • [[伊立替康]] • [[氟尿嘧啶]]</td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">竞品/来源</td>
                <td style="padding: 10px 15px; color: #334155;">[[FOLFIRI]] • [[FOLFOX]] • [[吉西他滨]]</td>
            </tr>
        </table>
    </div>

</div>